Artal Group S.A. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001053906
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2023 · 92 positions · Total reported value $2.93B · Top-10 concentration 77.4% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 33.3% · 1 new · 0 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q4 2023 13F filing, Artal Group S.A. disclosed 92 equity positions with a combined reported value of $2.93B. The filing implies a focused portfolio: its ten largest positions account for 77.4% of reported value. HoldingsHub classifies the profile as Mid / Focused / Consumer Tilt / High Turnover.
The largest disclosed positions as of Q4 2023 were CAVA ($1.38B), SRRK ($211.68M), LXRX ($179.86M). By sector, the heaviest allocations are Consumer Discretionary 47.8%, Health Care 36.4%. Versus the prior quarter, allocation shifted toward Health Care (+3.9pp), Consumer Discretionary (+2.1pp) and away from Other (-5.4pp).
Versus the prior quarter, Artal Group S.A. opened 1 new positions, trimmed 0 and fully exited 0, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 67% of names.
The largest new positions opened in Q4 2023 were ARGX ($44.28M), KRRO ($20.06M), PRTA ($18.22M).
Of the 8 positions fully exited versus the prior quarter, the largest were IMGN ($24.00M), VTYX ($14.07M), RYZB ($12.33M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2023)
- ARGX Argenx S.E. · $44.28M
- KRRO KORRO BIO INC · $20.06M
- PRTA PROTHENA CORP PLC · $18.22M
- LXEO LEXEO THERAPEUTICS INC · $8.10M
- CNTA CENTESSA PHARMACEUTICALS PLC · $8.06M
- CBAY CYMABAY THERAPEUTICS INC · $7.17M
- PDD PDD HOLDINGS INC · $4.75M
- GPCR STRUCTURE THERAPEUTICS INC · $3.53M
Fully Exited (vs previous quarter)
- IMGN IMMUNOGEN INC · prev qtr: $24.00M
- VTYX VENTYX BIOSCIENCES INC · prev qtr: $14.07M
- RYZB RAYZEBIO INC · prev qtr: $12.33M
- GERN GERON CORP · prev qtr: $11.80M
- NBTX NANOBIOTIX · prev qtr: $8.75M
- NTLA INTELLIA THERAPEUTICS INC · prev qtr: $8.73M
- AUPH AURINIA PHARMACEUTICALS INC · prev qtr: $7.77M
- VRDN VIRIDIAN THERAPEUTICS INC · prev qtr: $7.75M
Insider Transactions (Form 4)
Latest Artal Group S.A. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-15 | Sell | CAVA GROUP, INC. | 3,000,000 | $90.30 | SEC filing |
| 2026-04-30 | Opt exercise | LEXICON PHARMACEUTICALS, INC. | 20,421,735 | — | SEC filing |
Fund Profile
Artal Group S.A. is an SEC-registered 13F filer. As of Q2 2026 it reported 2 US equity positions with a combined value of $931.12M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 2 positions · $931.12M reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: CAVA (CAVA GROUP INC) at 54.9%
- Average position size: $465.56M
Sector Tilt
- Consumer Discretionary 54.9%
- Health Care 45.1%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 1 added, 1 reduced
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
32.01M | $1.38B | 47.01% | Hold | |
| 2 |
|
11.26M | $211.68M | 7.23% | Add | |
| 3 |
|
117.55M | $179.86M | 6.15% | Hold | |
| 4 |
|
1.21M | $101.38M | 3.46% | Reduce | |
| 5 |
|
1.42M | $85.08M | 2.91% | Reduce | |
| 6 |
|
404.48K | $72.95M | 2.49% | Hold | |
| 7 |
|
2.53M | $64.43M | 2.20% | Add | |
| 8 |
|
2.14M | $61.75M | 2.11% | Hold | |
| 9 |
|
1.62M | $58.96M | 2.02% | Reduce | |
| 10 |
|
3.00M | $52.11M | 1.78% | Add | |
| 11 |
|
1.70M | $48.64M | 1.66% | Reduce | |
| 12 |
|
116.39K | $44.28M | 1.51% | New | |
| 13 |
|
2.55M | $43.52M | 1.49% | Reduce | |
| 14 |
|
500.00K | $29.38M | 1.00% | Reduce | |
| 15 |
|
2.03M | $28.75M | 0.98% | Add | |
| 16 |
|
3.10M | $25.77M | 0.88% | Add | |
| 17 |
|
1.77M | $25.43M | 0.87% | Reduce | |
| 18 |
|
3.04M | $22.65M | 0.77% | Add | |
| 19 |
|
8.59M | $20.27M | 0.69% | Hold | |
| 20 |
|
418.61K | $20.06M | 0.69% | New | |
| 21 |
|
2.51M | $19.51M | 0.67% | Add | |
| 22 |
|
501.36K | $18.22M | 0.62% | New | |
| 23 |
|
802.90K | $17.23M | 0.59% | Hold | |
| 24 |
|
1.22M | $16.20M | 0.55% | Add | |
| 25 |
|
3.01M | $15.19M | 0.52% | Add | |
| 26 |
|
372.00K | $15.07M | 0.52% | Reduce | |
| 27 |
|
1.30M | $14.83M | 0.51% | Add | |
| 28 |
|
15.63M | $12.94M | 0.44% | Hold | |
| 29 |
|
200.00K | $12.53M | 0.43% | Hold | |
| 30 |
|
1.00M | $11.23M | 0.38% | Hold | |
| 31 |
|
300.00K | $10.74M | 0.37% | Reduce | |
| 32 |
|
4.72M | $10.06M | 0.34% | Hold | |
| 33 |
|
1.01M | $9.66M | 0.33% | Reduce | |
| 34 |
|
4.75M | $9.21M | 0.32% | Hold | |
| 35 |
|
603.43K | $8.10M | 0.28% | New | |
| 36 |
|
1.01M | $8.06M | 0.28% | New | |
| 37 |
|
2.50M | $8.05M | 0.28% | Hold | |
| 38 |
|
303.60K | $7.17M | 0.24% | New | |
| 39 |
|
68.00K | $7.07M | 0.24% | Reduce | |
| 40 |
|
3.66M | $6.48M | 0.22% | Hold | |
| 41 |
|
9.14M | $6.30M | 0.21% | Hold | |
| 42 |
|
1.81M | $6.12M | 0.21% | Reduce | |
| 43 |
|
200.00K | $6.12M | 0.21% | Add | |
| 44 |
|
2.05M | $5.75M | 0.20% | Hold | |
| 45 |
|
909.22K | $5.58M | 0.19% | Hold | |
| 46 |
|
2.35M | $5.28M | 0.18% | Reduce | |
| 47 |
|
700.00K | $5.11M | 0.17% | Hold | |
| 48 |
|
924.77K | $5.01M | 0.17% | Hold | |
| 49 |
|
32.50K | $4.75M | 0.16% | New | |
| 50 |
|
720.72K | $4.65M | 0.16% | Reduce | |
FAQ
What did Artal Group S.A. buy in 2023-Q4?
In its 2023-Q4 13F filing, Artal Group S.A. reported 92 equity positions worth $2.93B in aggregate; its largest disclosed positions were CAVA ($1.38B), SRRK ($211.68M), LXRX ($179.86M).
How large is Artal Group S.A.'s portfolio?
Artal Group S.A. reported $2.93B of long equity holdings across 92 positions as of 2023-Q4. Top-10 holdings account for 77.4% of reported value.
What is Artal Group S.A.'s investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Consumer Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.